

Legend

Plenary session	Networking session	Meet the Professor	Parallel session (Lupus)	Parallel session (ACA)	Free Communications	Industry session	Patient Program
-----------------	--------------------	--------------------	--------------------------	------------------------	---------------------	------------------	-----------------

The session marked with * is not included in the main event CME/CPD accreditation. For session details please see page xx.

Lecture titles in *italics* indicate oral abstract presentations.

For the times of individual lectures, please consult the mobile app or the interactive program online.

Sunday, 26 March 2017

	Melbourne 1
17:00-18:30	Opening Ceremony & Keynote Lecture Welcome to LUPUS 2017 – Eric F. Morand Welcome to ACA 2017 – Yehuda Shoenfeld Tribute to the late Professor Feng - CS Lau Keynote lecture: Bioprofiling in SLE - Virginia Pascual
18:30-19:30	Welcome Reception in the Exhibition Area

Monday 27 March, 2017

	Melbourne 1	Room 203-204	Room 210-211
07:30-08:30	Meet the Professor 1 East Meets West: Lupus Nephritis Daniel TM Chan Frederic Houssiau	Meet the Professor 2 So You Want to Do a Clinical Trial: a How-to Guide to Establishing Yourself as a Clinical Trial Center for SLE Mandana Nikpour Joan Merrill Richard Furie	Meet the Professor 3 Lupus in Pregnancy Aisha Lateef
08:30-10:30	Plenary 1 (Melbourne 1) Lupus in 2017: From Molecular Targets to New Therapies Chairs: Nan Shen, Virginia Pascual		

Legend

Plenary session	Networking session	Meet the Professor	Parallel session (Lupus)	Parallel session (ACA)	Free Communications	Industry session	Patient Program
-----------------	--------------------	--------------------	--------------------------	------------------------	---------------------	------------------	-----------------

	<p>Genetics and epigenetics as tools for elucidating SLE heterogeneity and pathogenesis - Lindsey Criswell</p> <p>Genome sequencing in SLE - Carola Vinuesa</p> <p>Stem cells and the treatment of SLE - LingYun Sun</p> <p><i>Abstract: Shared and endorgan specific transcriptional networks in skin versus kidney biopsies in systemic lupus</i> - C.C. Berthier</p> <p><i>Abstract: Confirmation of 5 novel susceptibility loci for SLE and integrated network analysis of 82 SLE susceptibility loci</i> - S. Nath</p>		
10:30-11:00	Coffee Break, Exhibition & Poster Viewing		
11:00-12:30	<p>Parallel 1 CNS Lupus Chairs: Yasuhiro Katsumata, Tim Godfrey</p> <p>Clinical heterogeneity, attribution and outcome - John Hanly</p> <p>Antibody-mediated neuropsychiatric lupus - Betty Diamond</p> <p><i>Abstract: Increased heterogeneity of brain perfusion is an early marker of central nervous system involvement in antiphospholipid antibody carriers</i> - T. Lin</p> <p><i>Abstract: The role of intracisternal deposited IgG in the pathogenesis of neuropsychiatric symptoms of SLE</i> - G. Deng</p>	<p>Parallel 2 Cell Targeting in SLE Chairs: Sarah Jones, CS Lau</p> <p>PDC targeting - Andrew Lew</p> <p>T cell targeting - Joe Craft</p> <p>B cell targeting - David Tarlinton</p> <p><i>Abstract: High salt promotes systemic lupus erythematosus by TET2-induced DNA demethylation and driving the differentiation of Thf cells</i> - H. Wu</p>	<p>Parallel 3 (ACA) From Genomics to Therapeutics via Structure Chairs: Matthew Cook, Carlo Perricone</p> <p>Uncovering the role of dark matter of genome in lupus - Nan Shen</p> <p>Molecular basis underpinning HLA association with disease - Jamie Rossjohn</p> <p>Development and trials of antigen-specific therapy in rheumatoid arthritis and type 1 diabetes: implications for lupus - Ranjeny Thomas</p> <p>Using related diseases to advance our understanding of genetic causes of autoimmunity - Matthew Brown</p>
12:30-14:15	Break, Exhibition & Poster Viewing		12:45-14:15 Industry Symposium*

Legend

Plenary session	Networking session	Meet the Professor	Parallel session (Lupus)	Parallel session (ACA)	Free Communications	Industry session	Patient Program
-----------------	--------------------	--------------------	--------------------------	------------------------	---------------------	------------------	-----------------

14:15-16:15	<p>Plenary 2 (Melbourne 1) Lupus Nephritis: From Bench to Bedside Chairs: Richard Kitching, Daniel TM Chan</p> <p>The science of lupus nephritis - Anne Davidson</p> <p>Biomarkers in lupus nephritis - Brad Rovin</p> <p>Treatment of lupus nephritis: My ten top tips - Frederic Houssiau</p> <p>Abstract: <i>Accelerated lupus nephritis associated with increased T helper subset, serum TNFa and anti dsDNA levels in pregnant pristane induced lupus mice</i> - K. Handono</p> <p>Abstract: <i>Impact of vascular involvement on outcomes in patients with lupus nephritis</i> - M. Rathi</p>						
16:15-16:45	Coffee Break, Exhibition & Poster Viewing						
16:45-18:15	<p>Parallel 4 Lupus Reflections Across the Continents: Are we Addressing the Needs of our Patients? Chairs: Fiona Goldblatt, John Esdaile</p> <p>Asia - Sandra Navarra</p> <p>North America - Jinoos Yazdany</p> <p>UK and Europe - Ian Bruce</p> <p>Abstract: <i>Capabilities of European lupus groups: members of lupus Europe</i> - K. Lerstrom</p>	<p>Parallel 5 Lupus Nephritis Chairs: Brad Rovin, Frederic Houssiau</p> <p>Resident kidney cells in the pathogenesis of lupus nephritis - Susan Yung</p> <p>Cross-talk between clinical and translational research in lupus nephritis - Daniel TM Chan</p> <p>What can we learn from studies of vasculitis? - Richard Kitching</p> <p>Abstract: <i>Aurion study: 24-week data of multi-target therapy with voclosporin, MMF and steroids for active lupus nephritis</i> - R. Huizinga</p>	<p>Parallel 6 (ACA) B Cells in SLE Pathogenesis and Therapeutics Chairs: David Tarlinton, Nan Shen</p> <p>Targeting the BAFF receptor TACI: A B cell-sparing therapeutic approach for SLE - Fabienne Mackay</p> <p>Secreted autoantibody repertoires in lupus and Sjögren's syndrome studied by proteomics - Tom Gordon</p> <p>Evidence for glucocorticoid induced leucine zipper as a regulator of B cell activation in SLE – Sarah Jones</p>				

Legend

Plenary session	Networking session	Meet the Professor	Parallel session (Lupus)	Parallel session (ACA)	Free Communications	Industry session	Patient Program
-----------------	--------------------	--------------------	--------------------------	------------------------	---------------------	------------------	-----------------

Tuesday, March 28, 2017

	Melbourne 1	Room 203-204	Room 210-211
07:30-08:30	<p>Meet the Professor 4 East Meets West: CNS Lupus Yoshiya Tanaka John Hanly</p>	<p>Meet the Professor 5 A Career in Lupus Research: Tips and Inspiration Fabienne Mackay Dafna Gladman CS Lau</p>	<p>Free Communications 1 Biomarker Discovery Chairs: David Tarlinton, Carola Vinuesa</p> <p>Abstract: <i>Towards patient stratification in SLE using baseline autoantibody signatures</i> - P. Budde</p> <p>Abstract: <i>Discovery and evaluation of a multiplexed mass spectrometry panel for measuring candidate peptide biomarkers in urine from patients with lupus nephritis</i> - V. Anania</p> <p>Abstract: <i>Peripheral immunophenotyping identifies three subgroups based on T cell heterogeneity in lupus patients</i> - S. Kubo</p> <p>Abstract: <i>Elucidating genetic pathways in SLE and stratifying patients via whole genome sequencing</i> - J. Ellyard</p> <p>Abstract: <i>Relevance of mouse lupus models of lupus nephritis to progression of CKD</i> - C. Berthier</p> <p>Abstract: <i>Gene expression profile from 1,760 SLE patients reveals novel</i></p>

Legend

Plenary session	Networking session	Meet the Professor	Parallel session (Lupus)	Parallel session (ACA)	Free Communications	Industry session	Patient Program
-----------------	--------------------	--------------------	--------------------------	------------------------	---------------------	------------------	-----------------

							<i>complex interferon responsive gene networks</i> - E. Dow
08:30-10:30	<p>Plenary 3 (Melbourne 1) Challenges in Drug Development and Clinical Trial Design in SLE Chairs: Marvin Fritzler, Tim Godfrey</p> <p>Clinical trials and tribulations - Joan Merrill</p> <p>Lessons learnt from RCTs in lupus nephritis - Daniel TM Chan</p> <p>The ideal trial design: a focus on patient selection and appropriate outcome measures - Richard Furie</p> <p><i>Abstract: Utility of the lupus low disease activity state (LLDAS) definition in discriminating responders in the phase IIB muse trial of anifrolumab in SLE – E. Morand</i></p> <p><i>Abstract: Efficacy and safety of Atacicept in patients with SLE: results of a 24-week randomized, placebo-controlled, phase IIB study</i> - J. Merrill</p>						
10:30-11:00	Coffee Break, Exhibition & Poster Viewing						
11:00-12:30	<p>Parallel 7 Manifestations, Comorbidities and Complications Chairs: Aisha Lateef, Sean O’Neill</p> <p>Cardiovascular disease/metabolic syndrome - Ian Bruce</p> <p>Lupus & Skin: Update 2017: Evaluation and management of cutaneous lupus erythematosus - Annegret Kuhn</p> <p>Infections in the Asia Pacific region - Worawit Louthrenoo</p>	<p>Parallel 8 Tregs and Tfh Cells in Autoimmunity Chairs: Eoin McKinney, Joe Craft</p> <p>Leptin: a new link between Tfh, Treg and autoimmunity - Di Yu</p> <p>Regulation of T cell subsets by low dose IL2 and its clinical relevance in SLE - Zhan-Guo Li</p> <p>T Follicular regulatory cells - Carola Vinuesa</p>	<p>Parallel 9 (ACA) The Mosaic of Autoimmunity Chairs: John Axford, Dimitrios Bogdanos</p> <p>Vasculitides in 2017 - Luc Mouthon</p> <p>Clinical significance of autoantibodies in myositis with interstitial lung disease - Tsuneyo Mimori</p> <p>Takayasu’s and polyangiitis - John Axford</p> <p><i>Abstract: The international consensus on standardized nomenclature of antinuclear antibody HEp-</i></p>				

Legend

Plenary session	Networking session	Meet the Professor	Parallel session (Lupus)	Parallel session (ACA)	Free Communications	Industry session	Patient Program
-----------------	--------------------	--------------------	--------------------------	------------------------	---------------------	------------------	-----------------

	<p>Abstract: <i>Myocardial diffusion weighted imaging reveals subclinical myocardial inflammation in patients with SLE</i> - Q. Yan</p>		<p><i>2 cell patterns (ICAP) initiative – its impact and update from 3rd ICAP</i> - E. Chan</p> <p>Abstract: <i>Drivers of the SLE responder index (SRI-5) endpoint in clinical trials of SLE</i> - K. Kalunian</p>
12:30-13:30	Break, Exhibition & Poster Viewing		
13:30-15:30	<p>Plenary 4 (Melbourne 1) Cutting Edge Science in SLE Chair: Anne Davidson, Eric Morand</p> <p>The role of innate immunity in SLE pathogenesis - Keith Elkon</p> <p>T cell fatigue in SLE - Eoin McKinney</p> <p>Accelerated Medicine Partnerships - Betty Diamond</p> <p>Abstract: <i>Bim suppresses the development of SLE by limiting macrophage inflammatory responses</i> - H. Perlman</p> <p>Abstract: <i>Single cell expression quantitative trait loci (eQTL) analysis of established lupus-risk loci in patient monocytes</i> - T. Niewold</p>		
15:30-16:00	Coffee Break, Exhibition & Poster Viewing		
16:00-17:30	<p>Free Communications 2 New Investigator Abstracts Chairs: Richard Kitching, Nicholas Wilson</p> <p>Abstract: <i>Long-term prognosis of patients with SLE-associated pulmonary arterial hypertension: cstar-PAH cohort study</i> - J. Zhao</p> <p>Abstract: <i>Urine tweak protein is a novel biomarker for resistant-</i></p>	<p>Parallel 10 Antiphospholipid Syndrome Chairs: Alberta Hoi, Fiona Goldblatt</p> <p>The pathogenesis of thrombosis in APS - Steven Krilis</p> <p>Thrombosis risk score and role of primary prophylaxis - Munther Khamashta</p> <p>Pregnancy in SLE, more than just anti-</p>	<p>Parallel 11 (ACA) Effector T Cells in SLE Chairs: Annegret Kuhn, Luc Mouthon</p> <p>Pathogenic T Cell Subsets in SLE - Joe Craft</p> <p>Immunophenotype and gene expression analysis - Tsutomu Takeuchi</p> <p>Immunometabolism defects in systemic lupus erythematosus: mechanisms and</p>

Legend

Plenary session	Networking session	Meet the Professor	Parallel session (Lupus)	Parallel session (ACA)	Free Communications	Industry session	Patient Program
-----------------	--------------------	--------------------	--------------------------	------------------------	---------------------	------------------	-----------------

	<p><i>to-treat lupus nephritis - T. Suttichet</i></p> <p><i>Abstract: Comparison of adverse effects and efficacy of high dose deflazacort versus high dose prednisolone in SLE patients - a prospective cohort study - A. Ganapati</i></p> <p><i>Abstract: RO52 autoantibodies arise from self-reactive progenitors in a mother of a child with neonatal lupus - J. Reed</i></p> <p><i>Abstract: Meta-analysis of low-dose aspirin in reducing risk of atherosclerosis cardiovascular disease in SLE patients - R.A. Nugraha</i></p> <p><i>Abstract: Inhibitory effect of resveratrol on oxidative stress in murine model of SLE - N. Pannu</i></p> <p><i>Abstract: Efficacy, damage accrual and predictors of response to belimumab in active SLE patients: a large italian multicenter prospective study - M. Larosa</i></p> <p><i>Abstract: Increased apoptosis and aberrant apoptosis signaling pathways of natural CD4+CD25+FOXP3+</i></p>	<p>phospholipid antibodies - Pier Luigi Meroni</p> <p><i>Abstract: Antiphospholipid score is a novel risk factor for idiopathic osteonecrosis - N. Ohnishi</i></p>	<p>therapeutic opportunities - Laurence Morel</p> <p><i>Abstract: Metabolic reprogramming in CD4+CD28-CXCR3intT-bethi cells and its relevance to pathogenesis in patients with SLE - S. Iwata</i></p>
--	---	---	--

Legend

Plenary session	Networking session	Meet the Professor	Parallel session (Lupus)	Parallel session (ACA)	Free Communications	Industry session	Patient Program
-----------------	--------------------	--------------------	--------------------------	------------------------	---------------------	------------------	-----------------

	<i>regulatory T cells in patients with SLE - L. Na</i>		
19:00	Congress Networking Event (at SEA LIFE Melbourne Aquarium)		

Wednesday, March 29, 2017

	Melbourne 1	Room 203-204	Room 210-211
07:30-08:30	Meet the Professor 6 East Meets West: Difficult Lupus Sandra Navarra CS Lau Alberta Hoi	Meet the Professor 7 Antiphospholipid Syndrome Munther Khamashta	Meet the Professor 8 Big Science in SLE and Autoimmune Disease Eoin McKinney
08:30-10:30	Plenary 5 (Melbourne 1) Outcome measures and treatment targets in SLE Chairs: Sandra Navarra, Sean O'Neill Measuring disease activity and damage in SLE - Dafna Gladman Remission as a treatment target in SLE - Andrea Doria Low disease activity as a treatment target in SLE - Mandana Nikpour Abstract: <i>Development and initial validation of a novel lupus disease activity index to account for glucocorticoids: SLEDAI-2K glucocorticoids index (SGI) - D. Gladman</i> Abstract: <i>Validation of a novel definition of low disease activity state in SLE - CS Lau</i>		
10:30-11:00	Coffee Break, Exhibition & Poster Viewing		
11:00-12:30	Parallel 12 Innate Immunity and Interferon Chair: Anne Davidson, Matthew Cook Autophagy regulates cytokines in innate	Parallel 13 Patient Program Module 1: What have we Learned about the Lupus? Chair: Barbara Ward	Parallel 14 (ACA) Pearls in Autoimmunity Chairs: Laurence Morel, Andrea Doria

Legend

Plenary session	Networking session	Meet the Professor	Parallel session (Lupus)	Parallel session (ACA)	Free Communications	Industry session	Patient Program
-----------------	--------------------	--------------------	--------------------------	------------------------	---------------------	------------------	-----------------

	<p>immune cells: A role in lupus? - James Harris</p> <p>Pre-clinical evaluation of a cytotoxic anti-IL-3Rα antibody that depletes plasmacytoid dendritic cells and suppresses IFNα production - Nicholas Wilson</p> <p>Abstract: <i>Cyclin dependent kinase 1: a novel regulator controlling type I interferon signaling and potential target for therapeutic intervention in SLE</i> - L. Wu</p> <p>Abstract: <i>A molecular signature based on IFN gene signature and serology defines two populations of patients with different baseline disease activity</i> - M. Petri</p> <p>Abstract: <i>Stimulator of interferon genes (STING) plays a crucial role in type-I IFN production induced by the sera from SLE patients</i> - Y. Kato</p>	<p>Causes, pathways and progression of lupus - Eric Morand</p> <p>Pregnancy journey - Susan Walker</p> <p>Challenge and triumph of kidney disease in SLE - Brad Rovin</p> <p>Cardiovascular risk in SLE - Ian Bruce</p>	<p>Nutrition and autoimmunity - Keonie Moore</p> <p>Autoimmunity associated lymphomas - Jorge Martins</p> <p>Harnessing autoimmunity (disease-specific autoantibody and its variant) in theranostics of disease - Eiji Matsuura</p>
12:30-13:30	Break, Exhibition & Poster Viewing	<p>Parallel 15</p> <p>Patient Program Module 2: The Changing Outlook for Treatment of Lupus Chair: Sandra Navarra</p> <p>Current therapies and changing perspective on managing lupus - Joan Merrill</p>	

Legend

Plenary session	Networking session	Meet the Professor	Parallel session (Lupus)	Parallel session (ACA)	Free Communications	Industry session	Patient Program
-----------------	--------------------	--------------------	--------------------------	------------------------	---------------------	------------------	-----------------

		Overview of new therapies in development for lupus - Richard Furie	
13:30-15:00	<p>Parallel 16 Quality of Care and Patient Reported Outcomes Chairs: Mandana Nikpour, Cynthia Aranow</p> <p>Advancing the Quality and Safety of Healthcare in SLE using Novel Clinical Informatics Approaches - Jinoos Yazdany</p> <p>The Challenges and Triumph of Integrated Model of Lupus Clinic in Australia - Alberta Hoi</p> <p>Abstract: <i>Disease outcomes and care fragmentation in SLE</i> - R. Ramsey-Goldman</p> <p>Abstract: <i>Association of the lupus low disease activity state (LLDAS) with health related quality of life</i> - V. Golder</p> <p>Abstract: <i>Comparison of remission and lupus low activity state as predictors of organ damage</i> - M. Petri</p>	<p>Parallel 17 Patient Program Module 3: Living and Coping with Lupus Chair: Barbara Ward</p> <p>Panel discussion</p> <p>Panelists:</p> <p>Michelle Leech</p> <p>Peter Gowdie</p> <p>Kathy Nicholls</p>	<p>Parallel 18 (ACA) Autoimmunity and the Environment Chairs: CS Lau, Dafna Gladman</p> <p>Pathogenesis and therapy in SLE - everything is microbiome, until proven otherwise - Yehuda Shoenfeld</p> <p>The HPV vaccine and SLE: a possible connection? - Carlo Perricone</p> <p>Infections and autoimmunity: the impact of the microbiome - Dimitrios Bogdanos</p> <p>Abstract: <i>A diet high in fibre can moderate inflammation and kidney pathology in a model of SLE</i> - T. Gottschalk</p> <p>Abstract: <i>Identification of disease-associated gut microbiota in lupus-prone BAFF-Tg mice</i> - W. Figgett</p>
15:00-15:30	Coffee Break		

Legend

Plenary session	Networking session	Meet the Professor	Parallel session (Lupus)	Parallel session (ACA)	Free Communications	Industry session	Patient Program
-----------------	--------------------	--------------------	--------------------------	------------------------	---------------------	------------------	-----------------

15:30-17:00	<p>Plenary 6 Changing the Script in Lupus – an Academia-Industry-Patient Roundtable Discussion Chair: Eric Morand</p> <p>Academia: Richard Furie, Joan Merrill, Daniel TM Chan</p> <p>Industry representatives: Marek Honczarenko (BMS), Christian Stach (UCB), Micki Hultquist (AstraZeneca), Damon Bass (GSK)</p> <p>Patient representatives: Duane Peters (LFA), Kirsten Lerstrom (Lupus Europe)</p> <p>1. The past: Perspectives on why so many trials have failed</p> <p>2. The present: What efforts have taken place to reduce the risk of failure in current/new trials?</p> <p>3. The future: What innovations in Lupus research will make the biggest impact on patients?</p>	<p>Parallel 19 Patient Program Module 4: Resources for Patients with Lupus and their Families Chair: Alberta Hoi</p> <p>Local resources for people with lupus featuring representatives of Australian groups</p> <p>Collaborating with people living with Lupus to innovate research - Sarah Boyd</p> <p>Lupus Care Pack - Corry Ang</p> <p>Lupus Exercise and Personal Medication Record - Dian Syarief</p> <p>World Lupus Federation – Information about global efforts to address lupus raise awareness and provide support services and advocacy to lupus patients and families around the world.</p> <p>Closing remarks - Duane Peters & Barbara Ward</p>	
17:00-17:30	<p>Congress Roundup Session</p> <p>New Investigator Awards Presentations</p> <p>Handover to Lupus 2019</p>		

Legend

Plenary session	Networking session	Meet the Professor	Parallel session (Lupus)	Parallel session (ACA)	Free Communications	Industry session	Patient Program
-----------------	--------------------	--------------------	--------------------------	------------------------	---------------------	------------------	-----------------